Cargando…

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study

INTRODUCTION: Due to their low CNS penetrance, there are concerns about the capacity of non-conventional PI-based ART (monotherapy and dual therapies) to preserve neurocognitive performance (NP). METHODS: We evaluated the NP change of aviremic participants of the SALT clinical trial [1] switching th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez Valero, Ignacio, Pasquau, Juan, Rubio, Rafael, Ribero, Antonio, Santos, Jose, Sanz, Jesus, Mariño, Ana, Crespo, Manel, Hernandez, Jose, Antonio Iribarren, Jose, Gutierrez, Felix, Terron, Alberto, Esteban, Herminia, Antonio Pérez-Molina, Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P124
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225372/ https://www.ncbi.nlm.nih.gov/pubmed/25394160 http://dx.doi.org/10.7448/IAS.17.4.19656

Ejemplares similares

Evaluation of periodontally diseased molars based on the Miller McEntire Periodontal Prognostic Index
por: Machado, Vanessa, et al.
Publicado: (2021)

INQUÉRITO SOROLÓGICO PARA SARS-COV-2 E DETECÇÃO VIRAL EM CRIANÇAS E ADOLESCENTES SUBMETIDOS AO TRANSPLANTE RENAL
por: de Morais, Richarlisson Borges, et al.
Publicado: (2022)

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study
por: López-Cortés, Luis F, et al.
Publicado: (2010)

Acute performance of stylet driven leads for left bundle branch area pacing: a comparison with lumenless leads
por: Cano Perez, O, et al.
Publicado: (2023)

Head up tilt test response patterns in patients undergoing cardioneuroablation
por: Viveros, D, et al.
Publicado: (2023)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus
por: Broquetas, Teresa, et al.
Publicado: (2022)

Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice
por: Cuenca-Gómez, José Ángel, et al.
Publicado: (2018)

Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review
por: de Fraga, Raquel Scherer, et al.
Publicado: (2020)

Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review
por: Abd El Aziz, Mohamed A, et al.
Publicado: (2020)

48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse
por: Xu, Wen-xiong, et al.
Publicado: (2018)

Tick Tock timing of permanent pacemaker implantation after transcatheter aortic valve replacement. A single center review
por: Rexha, E, et al.
Publicado: (2023)

Therapeutic options for syncope: a meta-analysis of trials with and without placebo control
por: Kaza, N, et al.
Publicado: (2023)

Cardioneuroablation for asystolic reflex syncope-left or right atrial approach? A randomized prospective Roman II study-preliminary results
por: Piotrowski, R, et al.
Publicado: (2023)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs
por: Gupta, Nidhi, et al.
Publicado: (2014)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Comment on “48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse”
por: Guo, Yafei, et al.
Publicado: (2019)

Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients
por: Micán, Rafael, et al.
Publicado: (2022)

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults
por: Gatell, Josép M, et al.
Publicado: (2014)

Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues
por: Broquetas, Teresa, et al.
Publicado: (2017)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity
por: Pastuch-Gawołek, Gabriela, et al.
Publicado: (2019)

Response to: Comment on “48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse”
por: Xu, Wen-xiong, et al.
Publicado: (2019)

An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Management of chronic hepatitis B patients: Efficacy & limitation of nucleos(t)ide analogues
por: Inoue, Jun, et al.
Publicado: (2011)

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
por: Cholongitas, Evangelos, et al.
Publicado: (2015)

Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
por: Moreno-Cubero, Elia, et al.
Publicado: (2018)

Distinct histological patterns in chronic hepatitis D with nucleos(t)ide analogue therapy
por: Hercun, Julian, et al.
Publicado: (2023)

Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B
por: Zhang, Ye, et al.
Publicado: (2017)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
por: Sonneveld, Milan J., et al.
Publicado: (2010)

Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
por: Aung, Myo Nyein, et al.
Publicado: (2010)

Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2018)

Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B
por: Choe, Jae Young, et al.
Publicado: (2017)

Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B
por: Roade, Luisa, et al.
Publicado: (2021)

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021)

Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives
por: De Castro, Federica, et al.
Publicado: (2023)

Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study
por: Cahn, Pedro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lmgvurir6che5an1pi3c83cn6a